Procalcitonin Levels Associate with Severity of Clostridium difficile Infection

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Rao, Krishna ^a,b   Walk, Seth T ^a,b   Micic, Dejan ^a   Chenoweth, Elizabeth ^a   Deng, Lili ^a,b   Galecki, Andrzej T ^a,b   Jain, Ruchika ^a,b   Trivedi, Itishree ^a   Yu, Marie ^a,b   Santhosh, Kavitha ^a,b   Ring, Cathrin ^a,b   Young, Vincent B ^a,b   Huffnagle, Gary B ^a,b   Aronoff, David M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL TOXIN; PROCALCITONIN;

ADULT; AGED; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; FEVER; HUMAN; MAJOR CLINICAL STUDY; MALE; ORGAN DYSFUNCTION SCORE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; REVIEW; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCITONIN; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROTEIN PRECURSORS; RECURRENCE; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84874677665     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058265     Document Type: Review

References (43)

1. Kuijper EJ, Coignard B, Tüll P, the ESGfCd, States EUM, et al. (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12: 2-18.
2. Bartlett JG, (2002) Antibiotic-Associated Diarrhea. N Engl J Med 346: 334-339.
3. Dubberke ER, Reske KA, Olsen MA, McDonald LC, Fraser VJ, (2008) Short- and Long-Term Attributable Costs of Clostridium difficile-Associated Disease in Nonsurgical Inpatients. Clin Infect Dis 46: 497-504.
4. McDonald LC, Owings M, Jernigan DB, (2006) Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 12: 409-415.
5. Redelings MD, Sorvillo F, Mascola L, (2007) Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 13: 1417-1419.
6. Burckhardt F, Friedrich A, Beier D, Eckmanns T, (2008) Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis 14: 691-692.
7. Gravel D, Miller M, Simor A, Taylor G, Gardam M, et al. (2009) Health Care-Associated Clostridium difficile Infection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 48: 568-576.
8. Gould CV, McDonald LC, (2008) Bench-to-bedside review: Clostridium difficile colitis. Crit Care 12: 203.
9. McDonald LC, Coignard B, Dubberke E, Song X, Horan T, et al. (2007) Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28: 140-145.
10. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31: 431-455.
11. Belmares J, Gerding DN, Tillotson G, Johnson S, (2008) Measuring the severity of Clostridium difficile infection: implications for management and drug development. Expert Rev Anti Infect Ther 6: 897-908.
12. Henrich TJ, Krakower D, Bitton A, Yokoe DS, (2009) Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15: 415-422.
13. Kyne L, Merry C, O'Connell B, Kelly A, Keane C, et al. (1999) Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing 28: 107-113.
14. Kyne L, Sougioultzis S, McFarland LV, Kelly CP, (2002) Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol 23: 653-659.
15. Das R, Feuerstadt P, Brandt LJ, (2010) Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with Clostridium difficile-associated disease. Am J Gastroenterol 105: 2040-2049.
16. Welfare MR, Lalayiannis LC, Martin KE, Corbett S, Marshall B, et al. (2011) Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score. J Hosp Infect 79: 359-363.
17. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, et al. (2009) Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302: 1059-1066.
18. Simon P, Milbrandt EB, Emlet LL, (2008) Procalcitonin-guided antibiotics in severe sepsis. Crit Care 12: 309.
19. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J, (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177: 498-505.
20. Hochreiter M, Kohler T, Schweiger AM, Keck FS, Bein B, et al. (2009) Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care 13: R83.
21. Schroeder S, Hochreiter M, Koehler T, Schweiger AM, Bein B, et al. (2009) Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study. Langenbeck's Archives of Surgery 394: 221-226.
22. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, et al. (2009) Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 34: 1364-1375.
23. Herrlinger KR, Dittmann R, Weitz G, Wehkamp J, Ludwig D, et al. (2004) Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis 10: 229-233.
24. Korczowski B, Szybist W, (2007) Serum procalcitonin and C-reactive protein in children with diarrhoea of various aetiologies. Acta Paediatr 93: 169-173.
25. Walk ST, Micic D, Jain R, Lo ES, Trivedi I, et al. (2012) Clostridium difficile Ribotype Does Not Predict Severe Infection. Clin Infect Dis 55: 1661-1668.
26. Hoste EA, Clermont G, Kersten A, Venkataraman R, Angus DC, et al. (2006) RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 10: R73.
27. Deyo RA, Cherkin DC, Ciol MA, (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45: 613-619.
28. Charlson ME, Pompei P, Ales KL, MacKenzie CR, (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40: 373-383.
29. Åkerlund T, Svenungsson B, Lagergren Å, Burman LG, (2006) Correlation of Disease Severity with Fecal Toxin Levels in Patients with Clostridium difficile-Associated Diarrhea and Distribution of PCR Ribotypes and Toxin Yields In Vitro of Corresponding Isolates. J Clin Microbiol 44: 353-358.
30. Dubberke ER, Sadhu J, Gatti R, Reske KA, DiPersio JF, et al. (2007) Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading system. Infect Control Hosp Epidemiol 28: 208-211.
31. Eyre DW, Walker AS, Wyllie D, Dingle KE, Griffiths D, et al. (2012) Predictors of First Recurrence of Clostridium difficile Infection: Implications for Initial Management. Clin Infect Dis 55: S77-S87.
32. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, et al. (2012) Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials. Clin Infect Dis 55: S93-S103.
33. Wilcox M, (2012) Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection. Clin Microbiol Infect 18: 13-20.
34. Humphries RM, Uslan DZ, Rubin Z (2012) Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol Available: http://jcm.asm.org/content/early/2012/12/20/JCM.02970-12.abstract. Accessed: 14 January 2013.
35. Warny M, Pepin J, Fang A, Killgore G, Thompson A, et al. (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366: 1079-1084.
36. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433-2441.
37. Cloud J, Noddin L, Pressman A, Hu M, Kelly C, (2009) Clostridium difficile strain NAP-1 is not associated with severe disease in a nonepidemic setting. Clin Gastroenterol Hepatol 7: 868.
38. Goldenberg SD, French GL, (2011) Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile. J Infect 62: 355-362.
39. Morgan OW, Rodrigues B, Elston T, Verlander NQ, Brown DF, et al. (2008) Clinical severity of Clostridium difficile PCR ribotype 027: a case-case study. PLoS One 3: e1812.
40. Venugopal AA, Riederer K, Patel SM, Szpunar S, Jahamy H, et al. (2012) Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. Scand J Infect Dis 44: 243-249.
41. Verdoorn BP, Orenstein R, Rosenblatt JE, Sloan LM, Schleck CD, et al. (2010) High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity. Diagn Microbiol Infect Dis 66: 24-28.
42. Schuetz P, Christ-Crain M, Huber AR, Müller B, (2010) Long-term stability of procalcitonin in frozen samples and comparison of Kryptor® and VIDAS® automated immunoassays. Clin Biochem 43: 341-344.
43. Meisner M, Tschaikowsky K, Schnabel S, Schmidt J, Katalinic A, et al. (1997) Procalcitonin-influence of temperature, storage, anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations. Eur J Clin Chem Clin Biochem 35: 597-601.